Prudential Financial Inc. acquired a new stake in Curis, Inc. (NASDAQ:CRIS) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 37,840 shares of the biotechnology company’s stock, valued at approximately $105,000.
Several other hedge funds also recently made changes to their positions in the company. Two Sigma Investments LP bought a new stake in shares of Curis during the fourth quarter valued at approximately $183,000. Metropolitan Life Insurance Co. NY increased its stake in shares of Curis by 7.3% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 82,518 shares of the biotechnology company’s stock valued at $254,000 after buying an additional 5,585 shares during the period. Janney Montgomery Scott LLC increased its stake in shares of Curis by 11.1% in the first quarter. Janney Montgomery Scott LLC now owns 123,644 shares of the biotechnology company’s stock valued at $344,000 after buying an additional 12,344 shares during the period. Renaissance Technologies LLC increased its stake in shares of Curis by 152.0% in the fourth quarter. Renaissance Technologies LLC now owns 361,100 shares of the biotechnology company’s stock valued at $1,112,000 after buying an additional 217,800 shares during the period. Finally, Teachers Advisors LLC increased its stake in shares of Curis by 62.5% in the fourth quarter. Teachers Advisors LLC now owns 368,278 shares of the biotechnology company’s stock valued at $1,134,000 after buying an additional 141,712 shares during the period. 51.67% of the stock is owned by institutional investors.
Curis, Inc. (NASDAQ CRIS) traded down 0.58% during trading on Tuesday, reaching $1.70. 341,007 shares of the company’s stock were exchanged. Curis, Inc. has a 12 month low of $1.60 and a 12 month high of $3.72. The stock’s market cap is $244.41 million. The firm has a 50 day moving average of $1.98 and a 200-day moving average of $2.32.
Curis (NASDAQ:CRIS) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.01. Curis had a negative net margin of 836.18% and a negative return on equity of 236.43%. The business had revenue of $2.10 million for the quarter, compared to analysts’ expectations of $2.08 million. During the same period last year, the business earned ($0.09) earnings per share. The company’s quarterly revenue was up 23.5% on a year-over-year basis. On average, equities research analysts anticipate that Curis, Inc. will post ($0.40) earnings per share for the current fiscal year.
Several brokerages have recently commented on CRIS. BidaskClub downgraded shares of Curis from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. ValuEngine raised shares of Curis from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Zacks Investment Research raised shares of Curis from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Curis in a research report on Friday, May 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. Curis has a consensus rating of “Hold” and a consensus price target of $5.88.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
